RECRUITINGOBSERVATIONAL

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study: Uptake, Outcome, and Risk Factors for Treatment Failures in a Real-world Setting

About This Trial

This study aims to characterize Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen, assess adherence to Swiss label indications, and describe treatment outcomes in this large, multicentre, heterogeneous, high-income setting. Moreover, the study aims to assess virological, immunological, demographic, clinical, and behavioural factors associated with viral failure under CAB+RPV LA regimen.

Who May Be Eligible (Plain English)

Who May Qualify: - Participant in the SHCS - All SHCS participants initiating the CAB+RPV LA regimen - All SHCS participants on SOC oral regimen Who Should NOT Join This Trial: - Not participating in the SHCS Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Participant in the SHCS * All SHCS participants initiating the CAB+RPV LA regimen * All SHCS participants on SOC oral regimen Exclusion Criteria: * Not participating in the SHCS

Treatments Being Tested

DRUG

VOCABRIA 30Mg Tablet

CAB 30 mg Film-coated tablets

DRUG

EDURANT 25Mg Tablet

RPV 25 mg film-coated tablets

DRUG

Cabotegravir Injectable Suspension

CAB LA 600 mg prolonged release suspension for injection (3 mL)

DRUG

Rilpivirine Injectable Suspension

RPV LA 900 mg prolonged release suspension for injection (3 mL)

BIOLOGICAL

Intact proviral DNA assay

HIV-1 latent reservoir size

BIOLOGICAL

Full-length sequencing

Proviral DNA

Locations (1)

University Hospital Zurich

Zurich, Switzerland